Zacks Investment Research cut shares of Corium International Inc. (NASDAQ:CORI) from a hold rating to a sell rating in a report issued on Tuesday.

According to Zacks, “Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. “

Several other research analysts also recently commented on CORI. Needham & Company LLC reissued a buy rating and issued a $15.00 price target on shares of Corium International in a report on Monday, September 26th. FBR & Co set a $18.00 price target on shares of Corium International and gave the company a buy rating in a report on Friday, August 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $11.92.

Shares of Corium International (NASDAQ:CORI) opened at 5.53 on Tuesday. Corium International has a 52-week low of $3.14 and a 52-week high of $9.93. The firm’s market capitalization is $123.65 million. The stock has a 50 day moving average of $5.79 and a 200-day moving average of $4.59.

Corium International (NASDAQ:CORI) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.08. Corium International had a negative net margin of 104.77% and a negative return on equity of 158.38%. Equities analysts expect that Corium International will post ($1.62) earnings per share for the current fiscal year.

A number of large investors have recently made changes to their positions in the company. RTW Investments LLC raised its stake in shares of Corium International by 3.0% in the second quarter. RTW Investments LLC now owns 852,961 shares of the biopharmaceutical company’s stock worth $2,960,000 after buying an additional 24,629 shares during the period. Franklin Resources Inc. raised its stake in shares of Corium International by 1.4% in the first quarter. Franklin Resources Inc. now owns 818,290 shares of the biopharmaceutical company’s stock worth $3,158,000 after buying an additional 11,200 shares during the period. Opaleye Management Inc. raised its stake in shares of Corium International by 1.4% in the first quarter. Opaleye Management Inc. now owns 360,000 shares of the biopharmaceutical company’s stock worth $1,390,000 after buying an additional 5,000 shares during the period. State Street Corp raised its stake in shares of Corium International by 82.4% in the first quarter. State Street Corp now owns 132,615 shares of the biopharmaceutical company’s stock worth $511,000 after buying an additional 59,905 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Corium International by 1.6% in the first quarter. Geode Capital Management LLC now owns 76,871 shares of the biopharmaceutical company’s stock worth $296,000 after buying an additional 1,187 shares during the period. 88.15% of the stock is currently owned by institutional investors and hedge funds.

About Corium International

Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.

5 Day Chart for NASDAQ:CORI

Receive News & Stock Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related stocks with our FREE daily email newsletter.